Cargando…

Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays

INTRODUCTION: In critically ill patients, the massive release of angiopoietin-2 (Ang-2) from endothelial Weibel–Palade bodies interferes with constitutive angiopoietin-1 (Ang-1)/Tie2 signaling in endothelial cells, thus leading to vascular barrier breakdown followed by leukocyte transmigration and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukasz, Alexander, Hellpap, Julian, Horn, Rüdiger, Kielstein, Jan T, David, Sascha, Haller, Hermann, Kümpers, Philipp
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575578/
https://www.ncbi.nlm.nih.gov/pubmed/18664247
http://dx.doi.org/10.1186/cc6966
_version_ 1782160334793998336
author Lukasz, Alexander
Hellpap, Julian
Horn, Rüdiger
Kielstein, Jan T
David, Sascha
Haller, Hermann
Kümpers, Philipp
author_facet Lukasz, Alexander
Hellpap, Julian
Horn, Rüdiger
Kielstein, Jan T
David, Sascha
Haller, Hermann
Kümpers, Philipp
author_sort Lukasz, Alexander
collection PubMed
description INTRODUCTION: In critically ill patients, the massive release of angiopoietin-2 (Ang-2) from endothelial Weibel–Palade bodies interferes with constitutive angiopoietin-1 (Ang-1)/Tie2 signaling in endothelial cells, thus leading to vascular barrier breakdown followed by leukocyte transmigration and capillary leakage. The use of circulating Ang-1 and Ang-2 as novel biomarkers of endothelial integrity has therefore gained much attention. The preclinical characteristics and clinical applicability of angiopoietin immunoassays, however, remain elusive. METHODS: We developed sandwich immunoassays for human Ang-1 (immunoradiometric sandwich assay/immunoluminometric sandwich assay) and Ang-2 (ELISA), assessed preanalytic characteristics, and determined circulating Ang-1 and Ang-2 concentrations in 30 healthy control individuals and in 94 critically ill patients. In addition, Ang-1 and Ang-2 concentrations were measured in 10 patients during a 24-hour time course with respect to interference by intravenous antibiotic treatment and by extended daily dialysis. RESULTS: The assays had detection limits of 0.12 ng/ml (Ang-1) and 0.2 ng/ml (Ang-2). Inter-assay and intra-assay imprecision was ≤8.8% and 3.7% for Ang-1 and was ≤4.6% and 5.2% for Ang-2, respectively. Angiopoietins were stable for 24 hours and were resistant to four freeze–thaw cycles. Angiopoietin concentrations were not associated with age, body mass index or renal function in healthy individuals. Ang-1 and Ang-2 concentrations correlated with severity of illness in critically ill patients. Angiopoietin concentrations were not influenced by antibiotic treatment or by extended daily dialysis. CONCLUSION: Ang-1 and Ang-2 might serve as a novel class of biomarker in critically ill patients. According to preclinical and clinical validation, circulating Ang-1 and Ang-2 can be reliably assessed by novel immunoassays in the intensive care unit setting.
format Text
id pubmed-2575578
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25755782008-10-30 Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays Lukasz, Alexander Hellpap, Julian Horn, Rüdiger Kielstein, Jan T David, Sascha Haller, Hermann Kümpers, Philipp Crit Care Research INTRODUCTION: In critically ill patients, the massive release of angiopoietin-2 (Ang-2) from endothelial Weibel–Palade bodies interferes with constitutive angiopoietin-1 (Ang-1)/Tie2 signaling in endothelial cells, thus leading to vascular barrier breakdown followed by leukocyte transmigration and capillary leakage. The use of circulating Ang-1 and Ang-2 as novel biomarkers of endothelial integrity has therefore gained much attention. The preclinical characteristics and clinical applicability of angiopoietin immunoassays, however, remain elusive. METHODS: We developed sandwich immunoassays for human Ang-1 (immunoradiometric sandwich assay/immunoluminometric sandwich assay) and Ang-2 (ELISA), assessed preanalytic characteristics, and determined circulating Ang-1 and Ang-2 concentrations in 30 healthy control individuals and in 94 critically ill patients. In addition, Ang-1 and Ang-2 concentrations were measured in 10 patients during a 24-hour time course with respect to interference by intravenous antibiotic treatment and by extended daily dialysis. RESULTS: The assays had detection limits of 0.12 ng/ml (Ang-1) and 0.2 ng/ml (Ang-2). Inter-assay and intra-assay imprecision was ≤8.8% and 3.7% for Ang-1 and was ≤4.6% and 5.2% for Ang-2, respectively. Angiopoietins were stable for 24 hours and were resistant to four freeze–thaw cycles. Angiopoietin concentrations were not associated with age, body mass index or renal function in healthy individuals. Ang-1 and Ang-2 concentrations correlated with severity of illness in critically ill patients. Angiopoietin concentrations were not influenced by antibiotic treatment or by extended daily dialysis. CONCLUSION: Ang-1 and Ang-2 might serve as a novel class of biomarker in critically ill patients. According to preclinical and clinical validation, circulating Ang-1 and Ang-2 can be reliably assessed by novel immunoassays in the intensive care unit setting. BioMed Central 2008 2008-07-29 /pmc/articles/PMC2575578/ /pubmed/18664247 http://dx.doi.org/10.1186/cc6966 Text en Copyright © 2008 Lukasz et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Lukasz, Alexander
Hellpap, Julian
Horn, Rüdiger
Kielstein, Jan T
David, Sascha
Haller, Hermann
Kümpers, Philipp
Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
title Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
title_full Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
title_fullStr Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
title_full_unstemmed Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
title_short Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
title_sort circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: development and clinical application of two new immunoassays
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575578/
https://www.ncbi.nlm.nih.gov/pubmed/18664247
http://dx.doi.org/10.1186/cc6966
work_keys_str_mv AT lukaszalexander circulatingangiopoietin1andangiopoietin2incriticallyillpatientsdevelopmentandclinicalapplicationoftwonewimmunoassays
AT hellpapjulian circulatingangiopoietin1andangiopoietin2incriticallyillpatientsdevelopmentandclinicalapplicationoftwonewimmunoassays
AT hornrudiger circulatingangiopoietin1andangiopoietin2incriticallyillpatientsdevelopmentandclinicalapplicationoftwonewimmunoassays
AT kielsteinjant circulatingangiopoietin1andangiopoietin2incriticallyillpatientsdevelopmentandclinicalapplicationoftwonewimmunoassays
AT davidsascha circulatingangiopoietin1andangiopoietin2incriticallyillpatientsdevelopmentandclinicalapplicationoftwonewimmunoassays
AT hallerhermann circulatingangiopoietin1andangiopoietin2incriticallyillpatientsdevelopmentandclinicalapplicationoftwonewimmunoassays
AT kumpersphilipp circulatingangiopoietin1andangiopoietin2incriticallyillpatientsdevelopmentandclinicalapplicationoftwonewimmunoassays